A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

  • End date
    Nov 16, 2022
  • participants needed
  • sponsor
    Massachusetts General Hospital
Updated on 29 December 2021
systemic therapy
growth factor
pleural effusion
liver metastasis
epidermal growth factor receptor
brain metastases
anaplastic lymphoma
targeted therapy
epidermal growth factor


This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) or or displaced anaplastic lymphoma receptor tyrosine kinase (ALK) or ROS proto-oncogene 1 (ROS1) gene (= oncogene-driven NSCLC) and for which the subject has been receiving treatment with a targeted biological agent such as erlotinib, crizotinib, or other drugs.


This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. The investigational intervention in this study is SBRT with proton or photon radiation (explained below). "Investigational" means that the intervention is being studied. SBRT and proton radiation therapy are FDA approved radiation delivery systems. However, using it as a treatment for stage IV NSCLC is still investigational.

SBRT is a specialized, technologically advanced type of external beam radiation therapy that pinpoints high doses of radiation directly on the cancer. Because of high precision, these treatments spare healthy tissue and are associated with fewer side effects. SBRT is very different from conventional therapy where radiation is delivered in small doses given daily over the course of several weeks. For SBRT, the total dose of radiation is typically administered in 4-5 daily sessions. SBRT can be delivered with standard, so called photon radiation, or proton beam. Neither of these two types of radiation is generally superior over the other. There are technical differences between these two, and depending on tumor location, size, shape, and other factors, the investigators will decide which type of radiation to use for which treatment.

After the screening procedures confirm you are eligible to participate in the research study:

  • Each participant will receive stereotactic treatment course (SBRT with protons or photons) to the area of their tumor.

Condition Non Small Cell Lung Cancer Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1), Targetable Oncogenes (EGFR, ALK, ROS1)
Treatment SBRT with protons or photons
Clinical Study IdentifierNCT02314364
SponsorMassachusetts General Hospital
Last Modified on29 December 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note